Know How Inpefa Stacks Up to Other SGLT2 Inhibitors

July 2023

New Inpefa (sotagliflozin) will try to compete with other SGLT2 inhibitors (Farxiga, Jardiance, etc).

Inpefa is NOT approved for managing type 2 diabetes yet...although A1c lowering seems similar to other SGLT2 inhibitors.

Instead, expect reps to tout Inpefa to reduce heart failure risk...especially for patients with a recent HF hospitalization.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology Know How Inpefa Stacks Up to Other SGLT2 Inhibitors
Heart Failure Consider Key Meds to Optimize HFpEF Regimens
Practice Continue to Address Nonmedical Factors Impacting Care
Menopause Clarify the Role of Veozah for Hot Flashes
Hypothyroidism Clear Up Misconceptions About Hypothyroidism
Allergic Reactions Be Specific When Recording an Allergy to Iodine
Warts Help Patients Manage Pesky Warts
Pediatrics Be Ready to Address Hypertension in Kids and Teens
Opioids Stay Alert for Opioid-Induced Hyperalgesia